Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

An interactive look at the drugs accounting for a fifth of Medicare’s spending

By Brian Buntz | August 31, 2023

Cost of drugs metaphor of money in a prescription bottle

[Christian Delbert/Adobe Stock]

As Medicare prepares to negotiate drug prices directly with pharma companies, the White House has selected 10 drugs that make up 20% — one-fifth — of Medicare’s annual spending. Our analysis provides a deep dive into these drugs, including their costs, the number of enrollees depending on them and the significant price hikes since their market debut. Here, we take a look at eight of the drugs with comprehensive data. Data comes courtesy of a CMS fact sheet and AARP research, which quantifies the degree of price escalations since the drugs’ debut.

Top drugs driving Medicare expenditures

This bubble chart displays the average costs per enrollee for a variety of Medicare Part D drugs, highlighting the percentage increase in price since their respective launches. Each bubble’s size corresponds to the total cost of the drug, with its color reflecting the dollar amounts of the price increase.

Leading the pack in terms of Medicare spending is blood clot treatment Eliquis, which drove $16.5 billion in spending from June 2022 to May 2023. Eliquis far surpassed the second-highest spender, the diabetes and heart failure drug Jardiance, which was responsible for just over $7 billion in spending. Close behind it was Xarelto, another blood clot drug, which drove roughly $6 billion in spending based on data gathered by AARP.

Diabetes drugs are a core focus for Medicare policy initiatives

Diabetes drugs were common among the top spenders, with Jardiance, Januvia, and Farxiga jointly accounting for more than $11.2 billion in spending. The White House also selected two other diabetes drugs, Fiasp and NovoLog, for potential price negotiations as part of the federal government’s initiative to control diabetes drug costs for Medicare enrollees. Additionally, President Biden’s Inflation Reduction Act capped the cost of insulin at $35 per month for almost four million seniors on Medicare. Big Pharma companies like Sanofi, which makes the most commonly prescribed insulin in the U.S., have preemptively slashed insulin prices. Earlier this year, Sanofi announced a 78% price reduction for its Lantus insulin and announced a $35 cap on out-of-pocket expenses for its customers. Other insulin makers announced similar moves.

A look at the number of Medicare Part D enrolls sheds light on Medicare’s Eliquis spending. More than 3.7 million enrollees rely on the drug as the drug plays a crucial role in treating and preventing blood clots, a condition common in the older community. Similarly, the collective spending on diabetes drugs Jardiance, Januvia and Farxiga mirrors the swelling diabetes rates among Medicare beneficiaries.

Key drugs straining Medicare’s budget

The table below rounds up eight drugs with an outsized impact on Medicare spending. It summarizes the drug indications, total costs to Medicare, the number of beneficiaries depending on these medications, their average costs per enrollee and the percentage increase in price since their market debut.

Drug Name Commonly Treated Conditions Total Part D Gross Covered Prescription Drug Costs (June 2022-May 2023) Number of Medicare Part D Enrollees (June 2022-May 2023) Average Part D Covered Prescription Drug Costs Per Enrollee Share of Current Price due to Price Increases (%)
Eliquis Prevention and treatment of blood clots $16,482,621,000 3,706,000 $4,448 55%
Jardiance Diabetes; Heart failure $7,057,707,000 1,573,000 $4,487 49%
Xarelto Prevention and treatment of blood clots; Reduction of risk for patients with coronary or peripheral artery disease $6,031,393,000 1,337,000 $4,511 63%
Januvia Diabetes $4,087,081,000 869,000 $4,703 73%
Entresto Heart failure $2,884,877,000 587,000 $4,915 44%
Enbrel Rheumatoid arthritis; Psoriasis; Psoriatic arthritis $2,791,105,000 48,000 $58,148 88%
Imbruvica Blood cancers $2,663,560,000 20,000 $133,178 52%
Stelara Psoriasis; Psoriatic arthritis; Crohn’s disease; Ulcerative colitis $2,638,929,000 22,000 $119,951 65%

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE